Barclays’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$97.9K Sell
6,000
-14,000
-70% -$263K ﹤0.01% 4314
2026
Q2
$302K Sell
20,000
-21,800
-52% -$381K ﹤0.01% 3494
2026
Q1
$801K Buy
+41,800
New +$908K ﹤0.01% 2889
2021
Q2
– Sell
-35,000
Closed -$3.09M – 5078
2021
Q1
$3.09M Buy
+35,000
New +$3.25M ﹤0.01% 1922

Other funds holding TNDM

Barclays's TNDM Position: Q3 2026 in Review

Barclays increased its Tandem Diabetes Care (TNDM) stake by 21% in Q3 2026, buying an estimated $1.4M and bringing the position to 425,185 shares worth $6.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1866.

Barclays first reported a position in TNDM in Q4 2013 and has held it in 49 quarters since. The position peaked at $20.2M in Q4 2025. 267 funds tracked by Wall St. Rank hold TNDM as of Q3 2026.

  • Barclays held 425,185 shares of Tandem Diabetes Care worth $6.93M as of Q3 2026.
  • Barclays bought 74,756 Tandem Diabetes Care shares in Q3 2026, an estimated $1.4M.
  • Tandem Diabetes Care made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1866 holding.
  • Barclays first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 49 quarters since.
  • Barclays's Tandem Diabetes Care position peaked at $20.2M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.